Cite
HARVARD Citation
Kimball, A. et al. (2023). Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials. Lancet. 401 (10378), pp. 747-761. [Online].